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Abstract
An abrupt increase of intracellular Ca
2+
 is observed in 
cells under hypoxic or oxidatively stressed conditions. 
The dysregulated increase of cytosolic Ca2+ triggers 
apoptotic cell death through mitochondrial swelling 
and activation of Ca2+-dependent enzymes. Transglu-
taminase 2 (TG2) is a Ca2+-dependent enzyme that cata-
lyzes transamidation reaction producing cross-linked 
and polyaminated proteins. TG2 activity is known to be 
involved in the apoptotic process. However, the 
pro-apoptotic role of TG2 is still controversial. In this 
study, we investigate the role of TG2 in apoptosis in-
duced by Ca2+-overload. Overexpression of TG2 in-
hibited the A23187-induced apoptosis through sup-
pression of caspase-3 and -9 activities, cytochrome c 
release into cytosol, and mitochondria membrane 
depolarization. Conversely, down-regulation of TG2 
caused the increases of cell death, caspase-3 activity 
and cytochrome c in cytosol in response to 
Ca
2+
-overload. Western blot analysis of Bcl-2 family 
proteins showed that TG2 reduced the expression level 
of Bax protein. Moreover, overexpression of Bax abro-
gated the anti-apoptotic effect of TG2, indicating that 
TG2-mediated suppression of Bax is responsible for 
inhibiting cell death under Ca2+-overloaded con-
ditions. Our findings revealed a novel anti-apoptotic 
pathway involving TG2, and suggested the induction 
of TG2 as a novel strategy for promoting cell survival 
in diseases such as ischemia and neurodegeneration.
Keywords: apoptosis; Bax; calcium; mitochondria; 
transglutaminase 2
Introduction
Precise regulation of free Ca2+ ion concentration in 
the cytosol is required for proper cellular signaling. 
A loss of Ca2+ homeostatic control, which is 
observed in heart and brain ischemia, over-sti-
mulation of receptor by neurotransmitters and 
treatment of cytotoxic agents, is a major cause of 
cell death (Orrenius et al., 2003). The cytosolic 
overload of Ca2+ triggers mitochondrial permea-
bility transition and cytochrome c release to cytosol 
that results in activation of caspases, the apoptotic 
executioners (Orrenius et al., 2003). Increased 
Ca2+ ion also activates Ca2+-dependent enzymes 
including phospholipases, calpain and endonu-
clease which can affect the determination of cell 
fate (Dong et al., 2006).
    Transglutaminase 2 (TG2) is a Ca2+-dependent 
enzyme that catalyzes acyl transfer reaction 
between the γ-carboxamide group of glutamine 
residues and the ε-amino group of lysine residues 
or polyamines (Lorand and Graham, 2003). In 
addition to Ca2+-dependent transamidation activity, 
TG2 also serves as a G-protein (Gh) that binds and 
hydrolyzes GTP (Nakaoka et al., 1994), and as an 
integrin-associated co-receptor that mediates the 
interaction of integrins with fibronectin (Akimov et 
al., 2000).
    TG2 has been reported to be induced in cells 
undergoing apoptosis in vivo (Fesus et al., 1987). 
TG2 thus has been suggested to inhibit the release 
of intracellular proteins and DNA from dying cells 
through catalyzing cross-linking of cellular proteins 
(Fesus et al., 1991). However, no difference in 
apoptosis between TG2 null thymocytes or mouse 
embryonic fibroblasts and wild type cells was 
observed when exposed to cytotoxic agents (De 
Laurenzi and Melino, 2001). Moreover, TG2 
expression protected cells from stress conditions 
such as a treatment with N-(4-hydroxyphenyl)reti-
namide (Antonyak et al., 2001), serum deprivation 
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Figure 1. TG2 inhibits A23187-induced cell death. (A) TG activity in HEK293 cells overexpressing TG2 (293TG2-2 and 293TG2-5). TG activity was ex-
pressed as relative value using HEK293 cells as a control. The level of TG2 expression was estimated by Western blot analysis (inset). (B) 
A23187-induced cell death in HEK293, 293TG2-2 and 293TG2-5 cells. Cell death was quantitated by trypan blue staining after 48 h of treatment with 5 μM 
A23187. (C) Time-dependent and dose-dependent cytotoxicity of A23187 in HEK293 and 293TG2-5 cells. (D) Flow cytometry analysis of A23187-induced 
apoptosis in HEK293 and 293TG2-5 cells determined by propidium iodide staining after treatment with 5 μM A23187. M1 represents sub-G1 population. 
Data represent the mean ± SD from three independent experiments. Asterisks indicate statistically significant differences (*, P ＜ 0.05; **, P ＜ 0.01) 
compared with HEK293 cells.
(Antonyak et al., 2003) and doxorubicin (Antonyak 
et al., 2004). Therefore, TG2 is suggested to have 
different roles in apoptosis depending on cell type 
or stress (Fesus and Szondy, 2005). 
    Recently, we showed that oxidative stress triggers 
an increase of Ca2+ ion which activates TG2 in 
human lens epithelial cell line. Subsequently, 
TG2-mediated protein modification lowers the 
solubility of protein and therefore leads to the 
aggregation of substrate proteins (Shin et al., 
2008). However, the role of TG2 in apoptosis 
induced by Ca2+-overload has not been elucidated. 
In this study, using TG2-overexpressed or down-re-
gulated cells, we showed that TG2 protects cells 
from Ca2+ ionophore-induced cell death by inhi-
biting mitochondria-mediated apoptotic pathway 
through regulation of Bax, a regulator of mito-
chondrial permeability transition.
Results
Inhibition of A23187-induced apoptosis by TG2
To investigate the role of TG2 in apoptosis induced 
by Ca2+-overload, we examined the viability of 
established HEK293 cell lines which exhibit 
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different levels of TG2 expression by treatment 
with Ca2+ ionophore. Western blot analysis and TG 
activity assay showed that the expression of TG2 
was undetectable in native HEK293 cells, 5-fold 
higher in 293TG2-2 cells, and 8.5-fold higher in 
293TG2-5 cells (Figure 1A). HEK293 cells and its 
derivative cell lines overexpressing TG2 showed 
no difference in cell viability under normal culture 
conditions employed in this study (data not shown). 
In HEK293 cells, treatment with 5 μM of A23187 
resulted in almost 50% of cell death after 48 h. By 
contrast, 293TG2-2 and 293TG2-5 cells were 
resistant to A23187-induced cell death (Figure 1B). 
There appears an inverse correlation between cell 
death rate and the level of TG2 expression (26.1% 
cell death for 293TG2-2 and 15.8% cell death for 
293TG2-5). The apparent protective effect of TG2 
against the A23187-induced cell death sustained 
over a period of 72 h and for up to 7.5 μM of 
A23187 (Figure 1C). To confirm these results, we 
examined apoptotic cell death by estimating the 
DNA content of A23187-treated cells after staining 
with propidium iodide. Flow cytometric analysis 
showed the increased percentage of sub-G1 
phase cells in HEK293 cells compared with 
293TG2-5 cells under the same experimental 
conditions (Figure 1D).
Inhibition of caspase activities by TG2
To understand the mechanism responsible for 
anti-apoptotic role of TG2, we examined the effect 
of TG2 overexpression on caspase-3 activity. In 
HEK293 cells, exposure to 5 μM A23187 induced 
the gradual increase of caspase-3 activity for up to 
48 h. By contrast, increase of caspase-3 activity in 
293TG2-5 cells was significantly lower than that in 
HEK293 cells (Figure 2A). Western blot analysis 
also showed that activated form of caspase-3 
appeared after 24 h in A23187-treated HEK293 
cells, whereas treatment of 293TG2-5 cells with 
A23187 resulted in decreased cleavage of cas-
pase-3 compared with control cells. These results 
were further verified by Western blot analysis of 
poly (ADP-ribose) polymerase (PARP) which 
showed decreased and delayed cleavage of PARP 
in 293TG2-5 cells compared with that of HEK293 
cells (Figure 2C).
Figure 2. TG2 inhibits caspase-3 and -9 activities of A23187-treated 
cells. (A) Caspase-3 activity of HEK293 and 293TG2-5 cells after treat-
ment with 5 μM A23187. Cell lysate (50 μg) was incubated with 2 mM 
Ac-DEVD-pNA, and caspase-3 activity was determined by measuring 
absorbance at 405 nm. Caspase-3 activity in the absence of A23187 
was expressed as 100%. (B) Caspase-9 activity in HEK293 and 
293TG2-5 cells after treatment with 5 μM A23187. Caspase-9 activity 
was determined by using Ac-LEHD-pNA as a substrate. Data represent 
the mean ± SD based on three independent experiments. Asterisks 
indicate statistically significant differences (*, P ＜ 0.05; **, P ＜ 0.01) 
compared with HEK293 cells. (C) Western blot analysis for caspase-3, 
poly (ADP-ribose) polymerase (PARP) and caspase-9.  
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Figure 3. TG2 inhibits cytochrome c release and mitochondria depolari-
zation of A23187-treated cells. (A) Western blot analysis of cytochrome c
after treatment with 5 μM A23187 for 48 h (C, cytosolic fraction; M, mi-
tochondrial fraction). α-tubulin and ATP synthase F1α were used as cy-
tosolic and mitochondrial markers, respectively. (B) Mitochondria mem-
brane potential was analyzed by FACS using JC-1 after treatment with 5 
μM A23187. A loss of mitochondria membrane potential was expressed 
as a relative percentage of cells showing reduced red fluorescence to 
that of the corresponding cells under the control condition. Asterisks in-
dicate statistically significant differences (*, P ＜ 0.05; **, P ＜ 0.01) 
compared with HEK293 cells.
    Caspase-9 is one of the upstream effecters of 
caspase-3 (Green, 1998). We then examined 
caspase-9 activity of HEK293 and 293TG2-5 cells. 
Treatment with A23187 increased caspase-9 
activity in HEK293 cells, but had no effect on the 
activity of caspase-9 in 293TG2-5 cells for up to 48 
hr (Figure 2B). Western blot analysis showed that 
cleavage of caspase-9 increased until 48 h and 
even full-length caspase-9 decreased at 72 h in 
HEK293 cells, whereas cleavage of caspase-9 
slightly increased only at 72 h in 293TG2-5 cells. 
These results indicate that TG2 inhibits 
A23187-induced activation of caspase-3 and 
caspase-9.
Inhibition of cytochrome c release and mitochondria 
depolarization by TG2 
We next sought to understand how TG2 could 
inhibit activities of caspases. Ca2+ ionophores 
induce the release of cytochrome c into cytoplasm 
from mitochondria (Orrenius et al., 2003). Cyto-
chrome c forms a complex with apoptosis pro-
tease-activating factor 1 (Apaf-1) and procaspa-
se-9, which activates caspase-3 (Acehan et al., 
2002). To test whether TG2 affects the Ca2+-indu-
ced release of cytochrome c, we compared the 
level of cytochrome c in cytosolic and mitochon-
drial fraction after treatment with A23187. Western 
blot analysis revealed a similar amount of 
cytochrome c in each fraction of HEK293 and 
293TG2-5 cells under normal culture conditions. 
Treatment with A23187 increased the cytochrome 
c in the cytosolic fraction of HEK293 cells with a 
concomitant decrease in mitochondrial fraction. By 
contrast, treatment with A23187 had minimal effect 
on the level of cytochrome c in both cytosolic and 
mitochondrial fraction of 293TG2-5 cells (Figure 3A), 
indicating that TG2 inhibits the release of 
cytochrome c from mitochondria by treatment of 
A23187.
    Mitochondria membrane depolarization is an 
early event in the apoptotic signaling cascade of 
mitochondria that precedes cytochrome c release 
(Honda et al., 2005). We therefore explored the 
possibility that TG2 might affect mitochondria 
membrane depolarization. Cells were incubated 
with JC-1 for 30 min and analyzed by flow cyto-
metry. A23187 induced mitochondria membrane 
depolarization of HEK293 and 293TG2-5 cells in a 
dose-dependent manner. However, in 293TG2-5 
cells, the magnitude of mitochondria membrane 
depolarization was suppressed, and was not 
further increased above 7.5 μM A23187 compared 
to HEK293 cells (Figure 3B). These results indicate 
that TG2 inhibits the release of cytochrome c 
through suppression of mitochondrial membrane 
depolarization.
    To further confirm the protective effect of TG2 in 
A23187-induced cell death, we established a HeLa 
cell line in which TG2 is down-regulated (Figure 
4A). When treated the cells with 5 μM of A23187 
for 48 h, TG2 knock-down cells showed the increase 
of cell death (Figure 4B), cleaved caspase-3 and 
cytochrome c in cytosolic fraction (Figure 4C) 
compared with those in control cells, verifying the 
prosurvival role of TG2. 
Down-regulation of Bax protein by TG2
It has been proposed that activated Bax or Bak is 
inserted into outer mitochondria membrane as a 
homo-oligomer to form channels through which 
cytochrome c is released (Cory et al., 2003). We 
therefore examined the expression of Bcl-2 family 
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Figure 4. Effects of TG2 knock-down on A23187-induced cell death. (A) TG activity of TG2 knock-down (HeLashTG2) and control (HeLashGFP) HeLa cells. 
TG activity is expressed as relative value using HeLashGFP cells as a control. The level of TG2 expression is estimated by Western blot analysis. (B) 
A23187-induced cell death in HeLashGFP and HeLashTG2 cells. Cell death was quantitated by trypan blue staining after 48 h of treatment with 5 μM A23187. 
(C) Western blot analysis of caspase-3 and cytochrome c after 48 h of treatment with 5 μM A23187 (C, cytosolic fraction; M, mitochondrial fraction). 
α-tubulin and ATP synthase F1α were used as cytosolic and mitochondrial markers, respectively. Asterisks indicate statistically significant differences (*, 
P ＜ 0.05; **, P ＜ 0.01) compared with HeLashGFP cells.
proteins after A23187 treatment. Western blot 
analysis showed that the levels of Bcl-2, Bcl-XL 
and phospho-Bad protein were similar in both cell 
lines. Interestingly, the level of Bax in 293TG2-5 cells 
was lower than that in HEK293 cells, and was 
further decreased after A23187 treatment (Figures 
5A and 5B). Using 293TG2-2 and 293TG2-5 cell lines, 
we found that the level of Bax was inversely 
correlated with that of TG2. Consistently, the level 
of Bax in TG2 knock-down HeLa cells was higher 
than that in control cells (Figure 5C). Moreover, 
transient overexpression of TG2 in HEK293 cells 
resulted in decrease of Bax level and transfection 
of shRNA expressing vector for TG2 in 293TG2-5 
cells increased the level of Bax protein (Figure 5D). 
    TG2 is reported to be required for translocation 
of Bax to mitochondria (Malorni et al., 2009). We 
thus examined the protein level of Bax in cytosolic 
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Figure 5. TG2 suppresses the protein level of Bax in the A23187-treated cells. (A, B) Western blot analysis of Bcl-2 family proteins after treatment with 5 
μM A23187 in HEK293 and 293TG2-5 cells at early (A) and late (B) time points. (C) Protein level of Bax in TG2-overexpressed HEK293 cells (293TG2-2 and 
293TG2-5) or in TG2-downregulated HeLa cells (HeLashTG2). (D) Protein level of Bax after transient transfection of TG2-expressing vector in HEK293 cells 
or TG2-knockdown vector (expressing shRNA for TG2; shTG2) in 293TG2-5 cells. (E) Protein level of Bax in cytosolic and mitochondrial fraction from 
HEK293 and 293TG2-5 cells after treatment with 5 μM A23187 for 48 h (C, cytosolic fraction; M, mitochondrial fraction). The numbers below the first pan-
el indicate relative densitomeric intensities of Bax proteins. Cytosolic and mitochondrial fractions were compared with cytosolic and mitochondrial fractions 
of untreated HEK293 cells, respectively. α-tubulin and ATP synthase F1α were used as cytosolic and mitochondrial markers, respectively. (F) 
Quantification of Bax mRNA in HEK293 and 293TG2-5 cells using conventional (upper panel) and real-time PCR method (lower panel). Hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) was used as internal control. (G) Effect of Bax expression on A23187-induced cell death in HEK293 and 293TG2-5 
cells. Cell death was quantitated by trypan blue staining after 48 h of treatment with 5 μM A23187. Asterisks indicate statistically significant differences (*, 
P ＜ 0.05) compared with vector-transfected 293TG2-5 cells.
and mitochondrial fraction (Figure 5E). In normal 
culture conditions, the level of Bax in mitochondrial 
fraction was lower in 293TG2-5 cells than in control 
cells. After treatment of A23187, the level of Bax in 
mitochondrial fraction of 293TG2-5 cells further 
decreased, suggesting that resistance to A23187-in-
duced apoptosis in 293TG2-5 cells is probably due 
to the low level of mitochondrial Bax. To test 
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Figure 6. Effect of MAPK expression on A23187-induc-
ed cell death. (A, B) Western blot analysis of FAK, Akt, 
ERK, p38, and JNK after treatment with 5 μM A23187 in 
HEK 293 and 293TG2-5 cells at early (A) and late (B) time 
points. Phosphorylated proteins are indicated as p-. 
Actin was employed as a loading control. (C) Effect of 
MAPK inhibitors on A23187-induced cell death. U0125 
(10 μm), SB203580 (5 μm) and SP600125 (10 μm) 
were used for inhibition of ERK, p38 and JNK, res-
pectively. Cell death was evaluated by trypan blue stain-
ing after 48 h of treatment with 5 μM A23187.
whether TG2 suppresses Bax expression at the 
transcriptional level, we quantitated the mRNA of 
Bax in both cell lines. On the contrary to protein 
level, the mRNA level of Bax was slightly increased 
in 293TG2-5 cells (Figure 5F), suggesting that low 
level of Bax protein is attributed to post-transcrip-
tional regulation. Moreover, the anti-apoptotic effect 
of TG2 was abrogated about 40% by over-
expression of Bax in 293TG2-5 cells (Figure 5G). 
These results indicate that TG2 inhibits cell death 
induced by Ca2+-overload through down-regulation 
of Bax protein, especially in mitochondria.
Effect of TG2 on MAPK activity
TG2 has been known to interact with α5β1 integrin 
that transmits intracellular signaling via FAK 
(Akimov et al., 2000; Parsons, 2003). MAPKs, 
downstream kinases of FAK, are involved in the 
regulation of cellular responses including apoptosis. 
The activation of JNK and p38 is associated with 
promotion of apoptosis, while ERK activity inhibits 
apoptosis (Reddy et al., 2003). To test whether 
TG2 inhibits Ca2+-induced apoptosis via interaction 
with integrin, we first examined the activity of FAK 
and its downstream kinases in HEK293 and 
293TG2-5 cells in response to A23187 treatment. 
The levels of p-FAK and p-Akt appeared similar in 
both cell lines. Under the same conditions, the 
level of p-ERK 1/2 was decreased after 24 h in 
both cell lines. The level of p-p38 was increased 
only in HEK293 cells, while that of p-JNK were 
646    Exp. Mol. Med. Vol. 42(9), 639-650, 2010
increased in 293TG2-5 cells (Figures 6A and 6B). 
We then examined the effect of MAPK inhibitors on 
A23187-induced cell death. Treatment with MAPK 
inhibitors had no effect on cell survival of HEK293 
as well as 293TG2-5 cells (Figure 6C), indicating 
that MAPK activities are not associated with 
anti-apoptotic role of TG2 in response to 
Ca2+-overload.
Discussion
Ca2+ has been suggested as an important regulator 
in the determination of cell fate. An abrupt increase 
of intracellular Ca2+ is found in various conditions 
including ischemia-reperfusion injury, receptor 
over-stimulation and oxidative stress (Orrenius et 
al., 2003). Increased cytosolic Ca2+ induces 
mitochondrial Ca2+ uptake, which causes mito-
chondrial swelling, mitochondrial membrane rupture, 
and cytochrome c release to cytosol. In the present 
study, we have demonstrated a mechanism for the 
anti-apoptotic role of TG2 under Ca2+-overloaded 
conditions. An increase of intracellular Ca2+ acti-
vated TG2 which in turn induced the down-re-
gulation of Bax protein. TG2-mediated regulation of 
Bax stabilized mitochondria membrane, suppre-
ssed the cytochrome c release, and subsequently 
inhibited the cell death. 
    The TG2-mediated modifications of substrate 
proteins have been implicated in many cellular 
processes including differentiation, cell adhesion, 
extracellular matrix formation and apoptosis 
(Lorand and Graham, 2003). However, the role of 
TG2 in apoptosis is still controversial. The suppre-
ssion of TG2 in U937 cells resulted in decreased 
cell death (Oliverio et al., 1999). Overexpression of 
TG2 sensitized neuronal cells to apoptosis 
(Piacentini et al., 2002) and activated caspase-3 in 
HEK293 cells (Milakovic et al., 2004). On the other 
hand, TG2 inhibits apoptosis induced by doxoru-
bicin (Antonyak et al., 2004), TNF-α (Kweon et al., 
2004), and dexamethasone (Nanda et al., 2001). 
Our findings, combined with the previous results, 
indicate that the role of TG2 in apoptosis depends 
on cell type as well as apoptogenic stress (Boehm 
et al., 2002; Tucholski and Johnson, 2002). Pre-
vious study showed conflicting results with our 
study in the role of TG2 in apoptosis induced by 
increase of intracellular Ca2+, in which, when 
transiently overexpressed, TG2 aggravated the 
thapsigargin-induced activation of caspase 3 
(Milakovic et al., 2004). However, although both 
A23187 and thapsigargin increase cytosolic Ca2+, 
activation of caspase-3 was observed only in 
thapsigargin-treated SK-N-SH cells (Humar et al., 
2009). In contrast to A23187, thapsigargin inhibits 
endoplasmic reticulum Ca2+-ATPase and thus 
induces the depletion of intracellular Ca2+ stores by 
long-term treatment, suggesting that machanism 
and kinetics of Ca2+ increase may affect the 
TG2-mediated regulation of Bax. In addition, 
subcellular localization of TG2 is also known to be 
associated with cellular response to apoptotic 
stimuli (Gundemir and Johnson, 2009). However, 
the effects of nuclear localization of TG2 varied 
depending on stimuli and conformational status of 
TG2. Therefore, further investigations are nece-
ssary to elucidate the mechanisms that determine 
the role of TG2 in the apoptotic process under 
various conditions.
    Bcl-2 protein family plays a pivotal role in 
apoptosis induced by Ca2+-overload. Ca2+ activates 
calcineurin which induces dephosphorylation of 
Bad (Orrenius et al., 2003). The dephosphorylated 
Bad activates Bax, which trigger the release of 
cytochrome c via the formation of mitochondria 
permeability transition pore. Indeed, the cells that 
were deficient of both Bax and Bak manifested a 
resistance to apoptosis induced by thapsigargin 
treatment (Wei et al., 2001), indicating the critical 
role of Bax in the apoptosis induced by 
Ca2+-overload. In this study, we showed the 
inverse correlation between TG2 and Bax expre-
ssion. Consistent with our results, Bax expression 
was increased by antisense oligonucleotide for 
TG2 (Lee et al., 2005). Although TG2 has been 
reported to modulate several transcription factors 
such as p53 (Tucholski, 2010), NF-κB (Jang et al., 
2010) and SP1 (Tatsukawa et al., 2009), at 
present, the molecular mechanism by which TG2 
regulates the expression level of Bax is unknown. 
One intriguing point is that the difference of protein 
level between control and 293TG2-5 cells was larger 
than that of mRNA level (Figures 5C and 5F), 
suggesting that TG2 regulates the expression of 
Bax at post-transcriptional level. Bax may be a 
substrate for TG2 and, therefore, TG2 forms a 
cross-linked multimer of Bax or mediates 
modifications of Bax, which promotes the formation 
of insoluble aggregates (Rodolfo et al., 2004). 
However, we could not detect any multimers of Bax 
in our experimental conditions. Recently, TG2 was 
suggested to decrease Bax stability through 
cross-linking and depletion of nucleophosmin, a 
Bax chaperone (Park et al., 2008).
    Our results have demonstrated that TG2 protects 
cells from Ca2+ overload by down-regulation of 
Bax. However, overexpression of Bax did not 
completely abrogate the protective effect of TG2 
(Figure 5G). Considering the protein levels of Bax, 
this result was partly due to low efficiency of 
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transient transfection in overexpressing Bax. 
Another possibility is the modulating effect of TG2 
on other survival factors than Bax, such as 
up-regulation of cellular inhibitor of apoptosis 2 
(cIAP2) and inhibition of caspase-3 under stressed 
conditions (Jang et al., 2010).  
    It has been reported that over-expression of 
TG2 in SK-N-BE cells resulted in hyperpolarization 
of mitochondrial membrane and MEFs prepared 
from TG2 knock-out mice exhibited hypopolarized 
mitochondrial membrane (Piacentini et al., 2002; 
Malorni et al., 2009). By contrast, our TG2-over-
expressed HEK293 cell lines showed similar 
mitochondrial membrane potential to control cell 
line in normal culture conditions. Role of TG2 in 
apoptotic process was reported to be different in a 
cell-type dependent manner. Therefore, it is likely 
that the effect of TG2 on mitochondrial membrane 
potential also seems to be cell-type dependent, 
which needs further investigations.
    TG2 has been proposed to have roles in the 
function of mitochondria. Since TG2 activity is 
detectable in mitochondria, many mitochondrial 
proteins including Bax, heat shock protein 60, 
prohibitin and ATP synthase β-chain are expected 
to be modified by TG2 (Rodolfo et al., 2004; 
Battaglia et al., 2007). TG2 deficient mice exhibited 
reduced activity of mitochondrial complex I, as well 
as reduced ATP level in heart and skeletal muscle 
after a prolonged physical exercise (Mastrobe-
rardino et al., 2006; Battaglia et al., 2007). Conse-
quently, the TG2 deficient mice were more 
vulnerable to a cardiac ischemia/reperfusion injury 
due to the defects in mitochondrial ATP production 
(Szondy et al., 2006). Taken together, these 
observations support our findings that TG2 inhibits 
mitochondria-mediated apoptosis triggered by an 
overload of intracellular Ca2+.
    Previous reports have suggested the involvement 
of TG2 in signal transduction of MAPKs pathways. 
ERK, p38 and JNK were activated by TG2 via the 
polyamination of RhoA in neuronal differentiation of 
SH-SY5Y cells (Singh et al., 2003). In calphostin 
C-induced apoptosis, TG2 was known to activate 
JNK in response to calphostin C (Robitaille et al., 
2008). Our results showed that TG2 activates ERK 
and JNK, while TG2 inhibit p38 in A23187-treated 
cells. Although effects of TG2 on MAPKs were not 
associated with cell death, role of TG2 in the 
regulation of MAPKs needs further investigation.
    In summary, we showed that TG2 inhibits 
A23187-induced apoptosis via the down-regulation 
of Bax expression. Our findings suggest that 
induction of TG2 expression could be a novel 
strategy to prevent apoptosis in ischemic diseases 
of brain and heart.
Methods
Establishment of cell lines that overexpress or 
down-regulate TG2
HEK293 cells that overexpress TG2 (293TG2-2 and 
293TG2-5) were established as described previously (Jeon 
et al., 2003). In brief, HEK293 cells were transfected in 
60-mm dish with full length cDNA (2 μg) of human TG2 in 
pcDNA3 (Invitrogen), or empty vectors, using Lipofecta-
mine (Invitrogen). Forty-eight hours after transfection, the 
cells were treated with 400 μg/ml geneticin (Invitrogen) for 
3 weeks. Geneticin-resistant clones were isolated and 
maintained for further analysis. HeLa cell lines that 
down-regulate TG2 (HeLashTG2) were established by 
transfection with pSUPER plasmid containing shRNA for 
TG2 or GFP. The target sequences for TG2 and GFP were 
5'-GGGCGAACCACCTGAACAA-3' and 5'-GCAAGCTGA-
CCCTGAAGTTC-3', respectively (Brummelkamp et al., 
2002; Hwa Kim et al., 2005). The cells were selected with 
800 μg/ml of geneticin for 2 weeks. The expression of TG2 
was confirmed by Western blot analysis.
TG activity assay 
TG activity was measured by microtiter plate method using 
N,N'-dimethylcasein and 5-(biotinamido)pentylamine (BP) 
as substrates (Slaughter et al., 1992). Briefly, 3 μg of 
N,N'-dimethylcasein in 100 μl coating buffer (50 mM 
Tris-Cl, pH 7.5, 150 mM NaCl, 5 mM EGTA, 5 mM EDTA) 
was added to each well of a 96-well microtiter plate. 
Subsequently, each well was overcoated with 200 μl of 3% 
bovine serum albumin (BSA) in phosphate buffered saline 
with 0.1% tween-20 (PBS-T) for 2 h at 37oC. After washing 
with PBS-T, cell lysate (50 μg of protein) and 50 μM BP in 
50 μl TG reaction buffer (50 mM Tris-Cl, pH 7.5, 10 mM 
CaCl2, 0.5% Triton X-100, 1 mM DTT) were added to the 
wells and incubated for 1 h at 37oC. To each well, 50 μl of 
horseradish peroxidase conjugated streptavidin (Jackson 
Laboratory) in PBS-T with 3% BSA was added and 
incubated for 1 hour at RT. After adding 50 μl of substrate 
solution (0.4 mg/ml o-phenylenediamine dihydrochloride in 
50 mM sodium citrate phosphate, pH 5.0), the plate was 
incubated for 15 min at RT. The reaction was stopped by 
adding 1M H2SO4, and the incorporation of BP was 
quantitated by measuring the absorbance at 490 nm using 
microplate spectrophotometer (Molecular Devices).
Apoptosis assay
Apoptotic cell death was determined by trypan blue 
exclusion assay or FACS analysis using propidium iodide. 
After A23187 treatment, cells were trypsinized and then 
centrifuged at 1,000 × g for 5 min. Both dead cells floating 
in the medium and the cells attached to the plate were 
recovered and resuspended in 500 μl medium. Trypan blue 
exclusion assay was performed using a kit (Invitrogen). For 
cytometric analysis, cells (1 × 106) were fixed in 70% 
ethanol and resuspended in 200 μl of PBS containing 50 
μg/ml propidium iodide and 100 μg/ml RNase A. After 
incubating for 30 min at RT, the cells were analyzed by 
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flow cytometry (Becton Dickinson) using the ModFit LT 
V3.0 software (Verity Software House). 
Caspase activity assay
Caspase activities were measured using chromogenic 
substrates, Ac-DEVD-pNA and Ac-LEHD-pNA (A.G. 
Scientific Inc.) for caspase-3 and caspase-9, respectively, 
as previously described with minor modifications (Gu et al., 
2003). The cells were lysed in buffer (50 mM HEPES, pH 
7.4, 0.1% CHAPS, 1 mM DTT, 0.1 mM EDTA and 0.1% 
Triton X-100) and centrifuged at 12,000 × g for 10 min at 
4oC. After determination of protein concentration BCA 
method (Pierce), the cell extract (50 μg of protein) was 
added to the assay buffer (100 mM HEPES, pH 7.4, 0.1% 
CHAPS, 10 mM DTT, 10% glycerol, and 2% (v/v) 
dimethylsulfoxide) containing chromogenic substrates (2 
mM) and incubated for 4 h at 37oC. Caspase activity was 
determined by measuring the absorbance at 405 nm 
according to the protocol (CaspACETM Assay System Kit; 
Promega).
Western blot analysis
Cells were lysed in buffer (50 mM Tris-Cl, pH 8.0, 150 mM 
NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxy-
cholate and protease inhibitor cocktail) and centrifuged at 
20,000 × g for 30 min at 4oC. After quantitating the protein 
concentration in each cell extract, the sample was 
subjected to SDS-PAGE and then transferred to nitroce-
llulose membrane. The membrane was blocked for 1 h with 
5% skim milk in Tris-buffered saline, and incubated with 
the following antibodies: anti-TG2 (Jeon et al., 2003), 
anti-caspase-3 (Cell signaling), anti-PARP (Cell signaling), 
anti-caspase 9 (cell signaling), anti-Bcl-2 (SantaCruz), 
anti-Bcl-XL (Cell Signaling), anti-p-Bad (Cell signaling), 
anti-Bax (SantaCruz), anti-FAK (Signal transduction), 
anti-p-FAK (Signal transduction), anti-Akt (Cell signaling), 
anti-p-Akt (Cell signaling), anti-ERK (SantaCruz), 
anti-p-ERK (SantaCruz), anti-p38 (Cell signaling), 
anti-p-p38 (Cell signaling), anti-p-JNK (SantaCruz), and 
anti-Actin (Sigma) antibody. Each membrane was washed 
and incubated with horseradish peroxidase-conjugated 
secondary antibody, followed by enhanced chemilumines-
cence development according to the manufacture’s 
instruction (Pierce).
Cytochrome c release from mitochondria 
Cytochrome c released from mitochondria was assessed 
as previously described (Waterhouse et al., 2001). In brief, 
cells were centrifuged at 1,000 × g for 5 min at 4oC and 
treated in PBS containing 80 mM KCl, 250 mM sucrose, 
and 200 μg/ml digitonin (Sigma) for 5 min on ice. The cells 
were centrifuged at 10,000 × g for 5 min at 4oC. The 
supernatant was used as cytosolic fraction. The pellet was 
lysed in buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 2 
mM EDTA, 2 mM EGTA, 0.2% Triton X-100 and 0.3% 
NP-40) rocking for 10 min at 4oC. The lysate was 
centrifuged at 10,000 × g for 5 min at 4oC. The super-
natant was used as mitochondrial fraction. Cytosolic 
fraction (30 μg) and mitochondrial fraction (5 μg) were 
subjected to Western blot analysis, using anti-cytochrome 
c antibody (Pharmingen). The protein level of Bax in each 
fraction was determined by Western blot analysis using 
anti-Bax antibody. Purity of fractions was estimated by 
Western blot analysis using anti-α-tubulin (cytosolic mar-
ker; Sigma) and anti-ATP synthase F1α (mitochondrial 
marker; MitoSciences) antibody. 
Assessment of mitochondria membrane 
depolarization
Mitochondria membrane depolarization was evaluated 
using the lipophilic cationic probe JC-1 (Molecular Probes) 
according to the manufacturer's instruction. Cells were 
harvested, resuspended in PBS, and incubated with 2 μM 
JC-1 rotating slowly for 30 min at 37oC. The cells were 
washed with PBS and analyzed by flow cytometry using 
488 nm excitation coupled with either 530/30 nm or 585/42 
nm bypass emission filter. The cells without red fluores-
cence were considered as the cells manifesting 
mitochondria membrane depolarization.
Real-time quantitative PCR
RNA was purified with TRIzol reagent (Invitrogen). One 
microgram of purified RNA was reversely transcribed using 
Maxime RT premix kit (Takara) according to the 
manufacturers' instructions. Quantitative real-time PCR 
was performed using SYBR Green PCR Master Mix 
(Applied Biosystems). Hypoxanthine phosphoribosyltrans-
ferase 1 (HPRT1) was used as internal control for 
normalization. The sequences of primers for Bax were 
5'-TCTACTTTGCCAGCAAACTGGTGC-3' and 5'-TGTCC-
AGCCCATGATGGTTCTGAT-3', and sequences for HPRT1 
were 5'-TGACACTGGCAAAACAATGCA-3' and 5'-GGT-
CCTTTTCACCAGCAAGCT-3' (Jang et al., 2009). Con-
ventional PCR was performed with same primers using Ex 
Taq polymerase (Takara).
Statistical analysis
All statistical calculations were performed using Prism 4.0 
(GraphPad). Differences between two variables and 
multiple variables were assessed by unpaired Student's t 
test and one-way ANOVA with Tukey's multiple com-
parison test, respectively. The difference was considered 
significant if the P value was less than 0.05. 
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